Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors

We have developed a next-generation sequencing assay to quantify biomarkers of the host immune response in formalin-fixed, paraffin-embedded (FFPE) tumor specimens. This assay aims to provide clinicians with a comprehensive characterization of the immunological tumor microenvironment as a guide for therapeutic decisions on patients with solid tumors. The assay relies on RNA-seq to semi-quantitatively measure the levels of 43 transcripts related to anticancer immune responses and 11 transcripts reflecting the relative abundance of tumor-infiltrating lymphocytes, as well as on DNA-seq to estimate mutational burden.

Source: Journal of Molecular Diagnostics - October 20, 2017 Category: Pathology Authors: Jeffrey M. Conroy, Sarabjot Pabla, Sean T. Glenn, Blake Burgher, Mary Nesline, Antonios Papanicolau-Sengos, Jonathan Andreas, Vincent Giamo, Felicia L. Lenzo, Fiona C.L. Hyland, Angela Omilian, Wiam Bshara, Moachun Qin, Ji He, Igor Puzanov, Marc S. Ernsto Tags: Regular Article Source Type: research